MediPal Holdings Corporation (7459)

Name: MediPal Holdings Corporation (7459) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

MediPal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. The company engages in the manufacture and supply of medical drugs, medical devices, medical supplies, clinical test reagents, and medical equipment and materials; non-life insurance agency business; outsourcing of medical office administration services; research and development of preventive medicine and cutting-edge medical technologies; and construction of a medical materials database.

Dati chiave

Capitalizzazione di mercato: JPY 598 billion
Ricavi (esercizio chiuso a 2026-03-31): JPY 3.82T
Utile netto: JPY 42.5B
Margine lordo: 6.8%
Margine netto: 1.1%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	JPY 3.82T	JPY 3.67T	JPY 3.56T	JPY 3.36T
Utile lordo	JPY 261.0B	JPY 255.8B	JPY 246.7B	JPY 224.3B
Risultato Operativo (EBIT)	JPY 53.2B	JPY 55.6B	JPY 47.3B	JPY 49.0B
Reddito netto	JPY 42.5B	JPY 40.3B	JPY 41.5B	JPY 38.8B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 7459. /companies/us/7459

Aziende simili

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.